Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Tetra Bio Pharma Inc TBPMQ

Tetra Bio-Pharma Inc. is a Canada-based cannabinoid-derived drug discovery and development company. The Company has developed a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. The Company has a pipeline of formulations and drug delivery systems with a portfolio of assets from the early research and development phase to advanced stage clinical programs. Its products include QIXLEEF, CAUMZ, PPP004, REDUVO, and REBORN 1. QIXLEEF is a botanical therapy with a fixed dosage of tetrahydrocannabinol (THC) and cannabidiol (CBD). CAUMZ is its inhaled cannabinoid-derived drug candidate. PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. REDUVO is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV) and weight loss and severe nausea in people living with human immunodeficiency virus (HIV) infection. REBORN 1 is in phase II trial.


GREY:TBPMQ - Post by User

Post by Golddetectoron Aug 17, 2021 8:56am
500 Views
Post# 33715920

Copy of Q3/4 catalysts

Copy of Q3/4 catalysts Nobody restored the earlier post so Copy and paste the catalysts below. 1st patient is out Reborn trial now few follow soon and nothing is out from Guy except the tweets that are encouraging but no nr yet. Non of the catalysts took place yet. Maybe he want to release closely to push sp up. We will find out soon I guess.
milestones as summarized in page 20 of TBP May 2021 presentation 

Short-Term Value-Creating Milestones
QIXLEEF - PLENITUDE:
Q2: ACCELERATE PATIENT ENROLMENT
Q3: RECEIVE OPINION FROM EMA – MALTA COMPETENT AUTHORITY
QIXLEEF – REBORN1:
Q2: 1ST PATIENT IN
Q3: INTERIM ANALYSIS
Q3: RECEIVE OPINION FROM EMA – MALTA COMPETENT AUTHORITY Q1-22: END OF ENROLMENT
ARDS-003:
Q4: LAST HEALTHY VOLUNTEER Q1-22: LAST PATIENT IN
CAU M Z:
BRIDGE TO QIXLEEF
R ED U VO :
Q4:DIN EXPECTED
ENJOUCA :
MARKET LAUNCH DATES: CANADA Q4 2021, AUSTRALIA Q1 2022, GERMANY Q2 2022


and presentation link below. It shows also the financial planning for the rest of the year


https://s24.q4cdn.com/136309390/files/doc_presentation/2021/06/2021.05.28_Tetra-Bio-Pharma_AGM-Presentation_FINAL.pdf
<< Previous
Bullboard Posts
Next >>